This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CLAAD Warns Of Increase In Prescription Drug Overdoses

Opioid Pain Relievers without Safety Features Could Return to the Market in January

WASHINGTON, Nov. 12, 2012 /PRNewswire-USNewswire/ -- Today, a national organization dedicated to reducing prescription drug abuse urged communities to take extra precautions to prevent medication overdoses.  The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) warned that pain pills without added safety features are expected to flood back into communities in the coming weeks unless the Food and Drug Administration (FDA) takes preventive action. 

In recent years, the makers of the powerful opioid pain relievers OxyContin and Opana removed their traditional products from the market in favor of new versions designed to impede certain forms of intentional abuse.  Preliminary, peer-reviewed evidence indicates that dealers and abusers have less interest in the new drugs with abuse-deterrent features.[1]  The new medications cost no more to consumers than their prior formulations. 

"Pharmaceutical companies have an obligation to make their products safer," said Michael Barnes, spokesman for CLAAD. 

Several drug companies have asked the FDA to approve generic versions of these medications that do not have abuse-deterrent properties.  The FDA could allow the old formulations of the drugs to return to market as early as January 2013. 

"Parents, health care providers, and law enforcement must be prepared to confront the resurgence of more readily abused pain medications, and the overdoses that could follow," Barnes said. 

Earlier this month, CLAAD and nine other public health and safety organizations sent a letter to the FDA urging it to take swift action to foster the widespread adoption of abuse-deterrent medications and to prevent the marketing of generic versions of the drugs that do not have similar safety features. 

A bill before the U.S. House of Representatives, H.R. 6160, would require all manufacturers of opioid pain relievers to utilize abuse-deterrent technologies.  However, the measure is not likely to pass before January.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs